US 7,582,745 B2
	Compositions and methods for inhibiting expression of Nav1.8 gene
Dinah Sah, Boston, Mass. (US); Maria Frank-Kamenetsky, Brookline, Mass. (US); Anke Geick, Bayreuth (Germany); Philipp Hadwiger, Altenkunstadt (Germany); Ingo Roehl, Memmelsdorf (Germany); Pamela Tan, Kulmbach (Germany); and Hans-Peter Vornlocher, Bayreuth (Germany)
Assigned to Alnylam Pharmaceuticals, Inc., Cambridge, Mass. (US)
Filed on Nov. 03, 2006, as Appl. No. 11/593,099.
Claims priority of provisional application 60/733816, filed on Nov. 04, 2005.
Claims priority of provisional application 60/741586, filed on Dec. 02, 2005.
Claims priority of provisional application 60/763202, filed on Jan. 26, 2006.
Claims priority of provisional application 60/795443, filed on Apr. 27, 2006.
Claims priority of provisional application 60/849364, filed on Oct. 04, 2006.
Prior Publication US 2007/0105806 A1, May 10, 2007
Int. Cl. C07H 21/04 (2006.01); A61K 31/70 (2006.01); C12N 5/00 (2006.01)

U.S. Cl. 536—24.5  [514/44; 435/325]

11 Claims

1. A double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a human Nav1.8 gene in a cell, wherein said dsRNA consists of a sense strand and an antisense strand that are complementary to each other, wherein said sense strand consists of SEQ ID NO:17 and said antisense strand consists of SEQ ID NO:18.